281 related articles for article (PubMed ID: 27685337)
1. Effect of antiviral therapy for HCV on lipid levels.
Mauss S; Berger F; Wehmeyer MH; Ingiliz P; Hueppe D; Lutz T; Simon KG; Schewe K; Rockstroh JK; Baumgarten A; Christensen S
Antivir Ther; 2017; 21(1):81-88. PubMed ID: 27685337
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Villalobos-Torres L; Muñoz Castillo I
Rev Esp Quimioter; 2018 Jun; 31(3):226-236. PubMed ID: 29771105
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
Suwanthawornkul T; Anothaisintawee T; Sobhonslidsuk A; Thakkinstian A; Teerawattananon Y
PLoS One; 2015; 10(12):e0145953. PubMed ID: 26720298
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients.
Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
Antivir Ther; 2017; 22(6):481-493. PubMed ID: 27934775
[TBL] [Abstract][Full Text] [Related]
6. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
El Sayed A; Barbati ZR; Turner SS; Foster AL; Morey T; Dieterich DT; Fierer DS;
HIV Clin Trials; 2017 Mar; 18(2):60-66. PubMed ID: 28183221
[TBL] [Abstract][Full Text] [Related]
8. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
Del Bello D; Cha A; Sorbera M; Bichoupan K; Levine C; Doyle E; Harty A; Patel N; Ng M; Gardenier D; Odin J; Schiano TD; Fierer DS; Berkowitz L; Perumalswami PV; Dieterich DT; Branch AD
Clin Infect Dis; 2016 Jun; 62(12):1497-1504. PubMed ID: 26936665
[TBL] [Abstract][Full Text] [Related]
9. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
10. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
[TBL] [Abstract][Full Text] [Related]
11. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
13. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD
World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650
[TBL] [Abstract][Full Text] [Related]
14. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
15. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
[TBL] [Abstract][Full Text] [Related]
16. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
17. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
Maasoumy B; Vermehren J; Welker MW; Bremer B; Perner D; Höner Zu Siederdissen C; Deterding K; Lehmann P; Cloherty G; Reinhardt B; Pawlotsky JM; Manns MP; Zeuzem S; Cornberg M; Wedemeyer H; Sarrazin C
J Hepatol; 2016 Sep; 65(3):473-82. PubMed ID: 27085252
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
[TBL] [Abstract][Full Text] [Related]
20. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.
Cacoub P; Bourliere M; Asselah T; De Ledinghen V; Mathurin P; Hézode C; Henry L; Stepanova M; Younossi ZM
Value Health; 2018 Oct; 21(10):1218-1225. PubMed ID: 30314623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]